Adaptimmune Therapeutics (ADAP) Scheduled to Post Earnings on Wednesday

Posted by Patrick Bannon on Nov 12th, 2024

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) is set to release its earnings data after the market closes on Wednesday, November 13th. Analysts expect Adaptimmune Therapeutics to post earnings of ($0.17) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) last posted its earnings results on Monday, August 12th. The biotechnology company reported $0.27 EPS for the quarter. Adaptimmune Therapeutics had a negative return on equity of 116.80% and a negative net margin of 51.25%. The firm had revenue of $128.23 million for the quarter, compared to analysts’ expectations of $58.00 million. On average, analysts expect Adaptimmune Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptimmune Therapeutics Price Performance

NASDAQ:ADAP opened at $0.82 on Tuesday. Adaptimmune Therapeutics has a 52 week low of $0.42 and a 52 week high of $2.05. The company has a quick ratio of 3.09, a current ratio of 3.09 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $210.76 million, a PE ratio of -2.35 and a beta of 2.26. The stock’s 50-day moving average price is $0.92 and its 200-day moving average price is $1.04.

Wall Street Analysts Forecast Growth

ADAP has been the topic of several recent research reports. StockNews.com upgraded Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Adaptimmune Therapeutics in a report on Tuesday, August 13th.

Check Out Our Latest Report on ADAP

About Adaptimmune Therapeutics

(Get Free Report)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.